Hennion & Walsh Asset Management Inc. Purchases 95,855 Shares of ImmunityBio, Inc. $IBRX

Hennion & Walsh Asset Management Inc. lifted its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 31.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 402,639 shares of the company’s stock after acquiring an additional 95,855 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in ImmunityBio were worth $797,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in IBRX. Skandinaviska Enskilda Banken AB publ lifted its holdings in shares of ImmunityBio by 347.7% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 1,324,871 shares of the company’s stock valued at $3,246,000 after purchasing an additional 1,028,921 shares in the last quarter. Heights Capital Management Inc. bought a new stake in ImmunityBio in the 3rd quarter worth about $16,152,000. Vanguard Group Inc. increased its holdings in ImmunityBio by 26.8% in the 3rd quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company’s stock worth $68,032,000 after buying an additional 5,837,898 shares in the last quarter. Armistice Capital LLC purchased a new position in ImmunityBio in the 2nd quarter worth about $20,497,000. Finally, Rafferty Asset Management LLC lifted its stake in ImmunityBio by 79.2% during the 3rd quarter. Rafferty Asset Management LLC now owns 452,458 shares of the company’s stock valued at $1,113,000 after acquiring an additional 199,990 shares during the period. 8.58% of the stock is currently owned by hedge funds and other institutional investors.

Key ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Neutral Sentiment: Investment coverage shift: A Seeking Alpha author downgraded IBRX to Hold, arguing investors shouldn’t rush into buying amid current uncertainty. Read More.
• Negative Sentiment: Regulatory trigger cited by plaintiffs: Hagens Berman links the class action to an FDA warning over allegedly unsupported cancer?treatment claims about Anktiva and says roughly $2B of market cap was erased. This FDA allegation is the core factual basis for many complaints and increases litigation risk and reputational damage. Read More.
• Negative Sentiment: Multiple law firms have filed or announced securities?fraud suits and are soliciting lead plaintiffs (Robbins Geller, Kessler Topaz, Rosen, Pomerantz, Faruqi, DJS, Schall, Glancy, etc.), all alleging material misstatements/omissions about Anktiva during Jan. 19–Mar. 24, 2026. The proliferation of filings signals heightened class action exposure and potential aggregation of claims. Example filing/notice: Robbins Geller. Read More.
• Negative Sentiment: Solicitation & deadline notices continue: Multiple press releases and attorney announcements remind investors of the May 26, 2026 lead?plaintiff deadline, increasing publicity and the likelihood of more claimants joining suits (examples: Rosen, PR Newswire). Read More.
• Negative Sentiment: Local/regional coverage amplifies reach: Additional alerts from firms (Kessler Topaz, Hagens Berman, Glancy, ClaimsFiler, DJS, Schall, etc.) broaden investor awareness and could increase short?term selling pressure as legal risk and regulatory concerns are priced in. Read More.

ImmunityBio Stock Performance

IBRX opened at $7.30 on Friday. The firm’s 50 day simple moving average is $7.74 and its two-hundred day simple moving average is $4.38. The company has a market capitalization of $7.51 billion, a PE ratio of -19.21 and a beta of 0.13. ImmunityBio, Inc. has a 1-year low of $1.83 and a 1-year high of $12.43.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings data on Monday, February 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The business had revenue of $38.29 million for the quarter. Equities analysts forecast that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on IBRX. BTIG Research started coverage on shares of ImmunityBio in a research note on Thursday, March 12th. They issued a “buy” rating and a $13.00 price target for the company. Weiss Ratings restated a “sell (e+)” rating on shares of ImmunityBio in a report on Monday, December 29th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a research report on Monday, February 23rd. HC Wainwright boosted their target price on shares of ImmunityBio from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, February 23rd. Finally, D. Boral Capital restated a “buy” rating and issued a $23.00 price target on shares of ImmunityBio in a research note on Monday, March 23rd. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, ImmunityBio presently has an average rating of “Moderate Buy” and an average price target of $14.40.

Insider Transactions at ImmunityBio

In related news, Director Barry J. Simon sold 75,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $12.01, for a total transaction of $900,750.00. Following the completion of the transaction, the director directly owned 2,850,821 shares in the company, valued at approximately $34,238,360.21. The trade was a 2.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Christobel Selecky sold 25,000 shares of the stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 501,967 shares of company stock valued at $4,466,412. Company insiders own 69.48% of the company’s stock.

ImmunityBio Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.